Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review

Abstract

Objective

To provide a state of the art review of intranasal antiviral drug delivery and to discuss current applications, adverse reactions, and future considerations in the management of coronavirus disease 2019 (COVID-19).

Data Sources

PubMed, Embase, and Clinicaltrials.gov search engines.

Review Methods

A structured search of the current literature was performed of dates up to and including April 2020. Search terms were queried as related to topics of antiviral agents and intranasal applications. A series of video conferences was convened among experts in otolaryngology, infectious diseases, public health, pharmacology, and virology to review the literature and discuss relevant findings.

Conclusions

Intranasal drug delivery for antiviral agents has been studied for many years. Several agents have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases.

Implications for Practice

Intranasal drug delivery represents an important area of research for COVID-19 and other viral diseases. The consideration of any potential adverse reactions is paramount.

Keywords

coronavirus COVID-19 antiviral agents nasal nasopharynx public health severe acute respiratory syndrome coronavirus 2 otolaryngology

Get full access to this article

View all access options for this article.

References

Chin

AWH

Chu

JTS

Perera

MRA

, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet. Published online April 2, 2020. doi:10.1016/S2666-5247(20)30003-3

Arons

Hatfield

Reddy

, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. Published online April 24, 2020. doi:10.1056/NEJMoa2008457

Lytras

Dellis

Flountzi

, et al. High prevalence of SARS-CoV-2 infection in repatriation flights to Greece from three European countries. J Travel Med. 2020;27(3):taaa054.

Nishiura

Kobayashi

Miyama

, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154-155.

Lau

EHY

, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-675.

Cascella

Rajnik

Cuomo

Dulebohn

Di Napoli

. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls; 2020.

Fehr

Perlman

. Coronaviruses: An Overview of Their Replication and Pathogenesis. Springer; 2015.

Shereen

Khan

Kazmi

Bashir

Siddique

. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.

Shang

Shi

, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.

10.

Chan

JF-W

Kok

K-H

Zhu

, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236.

11.

Loeffelholz

Tang

Y-W

. Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerg Microbes Infect. 2020;9:747-756.

12.

Wang

Gao

, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.

13.

Pittet

Allegranzi

Boyce

. The World Health Organization guidelines on hand hygiene in health care and their consensus recommendations. Infect Control Hosp Epidemiol. 2009;30:611-622.

14.

Rabenau

Kampf

Cinatl

Doerr

. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect. 2005;61:107-111.

15.

Siddharta

Pfaender

Vielle

, et al. Virucidal activity of World Health Organization–recommended formulations against enveloped viruses, including Zika, Ebola, and emerging coronaviruses. J Infect Dis. 2017;215:902-906.

16.

Centers for Disease Control and Prevention. CDC statement for healthcare personnel on hand hygiene during the response to the international emergence of COVID-19. Published May 17, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/hand-hygiene.html

17.

Kratzel

Todt

V’kovski

, et al. Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. Emerg Infect Dis. 2020;26(7). doi:10.3201/eid2607.200915

18.

Steed

Costello

Lohia

Jones

Spannhake

Nguyen

. Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control. 2014;42:841-846.

19.

Eggers

. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8:581-593.

20.

Safety and efficacy information 3M kin and nasal antiseptic (povidone-iodine solution 5% q/q [0.5% available iodine] USP) patient preoperative skin preparation. Accessed April 24, 2020. https://multimedia.3m.com/mws/media/716788O/3m-skin-and-nasal-antiseptic-safety-and-efficacy-brochure.pdf

21.

Rezapoor

Nicholson

Tabatabaee

Chen

Maltenfort

Parvizi

. Povidone-iodine-based solutions for decolonization of nasal Staphylococcus aureus: a randomized, prospective, placebo-controlled study. J Arthroplasty. 2017;32:2815-2819.

22.

Wada

Nojima

Ogawa

, et al. Relationship between virucidal efficacy and freeiodine concentration of povidone-iodine in buffer solution. Biocontrol Sci. 2016;21(1):21-27.

23.

Kim

Rimmer

Mrad

Ahmadzada

Harvey

. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol. 2015;129:S45-S50.

24.

Ramezanpour

Smith

JLP

Psaltis

Wormald

Vreugde

. In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells. Int Forum Allergy Rhinol. Published online April 6, 2020. doi:10.1002/alr.22575

25.

Mady

Kubik

Baddour

Snyderman

Rowan

. Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as “personal protective equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020;105:104724.

26.

Kirk-Bayley

Combes

Sunkaraneni

Challacombe

. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers. SSRN. Published online May 4, 2020. doi:10.2139/ssrn.3563092

27.

Choi

Park

Son

Cheon

. Aspiration pneumonitis due to povidone-iodine aspiration during a facial bone fracture reduction operation. J Craniofac Surg. 2014;25(2):e172-e174.

28.

Hwang

Vukkadala

. PVP-I nasal sprays and SARS-CoV-2 nasopharyngeal titers (for COVID-19). Accessed May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04347954

29.

Khan

. A clinical trial of gargling agents in reducing intraoral viral load among COVID-19 patients. Accessed May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04341688.

30.

Mimoz

Seguin

. Povidone iodine mouthwash, gargle, and nasal spray to reduce naso- pharyngeal viral load in patients with COVID-19. Accessed May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04371965

31.

Rickert

Moses

. Gargling and nasal rinses to reduce oro- and nasopharyngeal viral load in patients with COVID-19. Accessed May 4, 2020. https://clinicaltrials.gov/ct2/show/NCT04344236

32.

Eccles

Winther

Johnston

Robinson

Trampisch

Koelsch

. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial. Respir Res. 2015;16:121.

33.

Ludwig

Enzenhofer

Schneider

, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res. 2013;14:124.

34.

Gern

Mosser

Swenson

, et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195:1137-1143.

35.

Brown

Nwokeji

Rascati

Zachry

Phillips

. Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providers. Adm Policy Ment Health. 2009;36:278-287.

36.

Rennie

Bowtell

Hull

Charbonneau

Lambkin-Williams

Oxford

. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res. 2007;8:38.

37.

Ramalingam

Graham

Dove

Morrice

Sheikh

. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Sci Rep. 2019;9:1015.

38.

Ramalingam

Cai

Wong

, et al. Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep. 2018;8:13630.

39.

Kanjanawasee

Seresirikachorn

Chitsuthipakorn

Snidvongs

. Hypertonic saline versus isotonic saline nasal irrigation: systematic review and meta-analysis. Am J Rhinol Allergy. 2018;32:269-279.

40.

Kampf

Todt

Pfaender

Steinmann

. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246-251.

41.

Goyal

Chander

Yezli

Otter

. Evaluating the virucidal efficacy of hydrogen peroxide vapour. J Hosp Infect. 2014;86:255-259.

42.

Mak

JWY

Chan

FKL

. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol. Published online April 24, 2020. doi:10.1016/S2468-1253(20)30122-9

43.

Lehtinen

Hibberd

Mannikko

, et al. Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge. Sci Rep. 2018;8:11411.

44.

Kanmani

Clua

Vizoso-Pinto

, et al. Respiratory commensal bacteria Corynebacterium pseudodiphtheriticum improves resistance of infant mice to respiratory syncytial virus and streptococcus pneumoniae superinfection. Front Microbiol. 2017;8:1613.

45.

Zelaya

Tada

Vizoso-Pinto

, et al. Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage. Inflamm Res. 2015;64:589-602.

46.

Rosen

Palmer

O’Malley

BW, Jr.

Cohen

. Surfactants in the management of rhinopathologies. Am J Rhinol Allergy. 2013;27:177-180.

47.

Numata

Mitchell

Tipper

, et al. Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models. J Biol Chem. 2020;295:1704-1715.

48.

Voelker

Numata

. Phospholipid regulation of innate immunity and respiratory viral infection. J Biol Chem. 2019;294:4282-4289.

49.

Wang

, et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020;367(6480):eaau0810.

50.

Kimura

. Impact of nasal saline irrigations on viral load in patients with COVID-19. Accessed May 12, 2020. https://clinicaltrials.gov/ct2/show/NCT04347538

51.

Turner

Dorminy

Chandra

. Safety and tolerability of surfactant nasal irrigation. Int Forum Allergy Rhinol. 2017;7:809-812.

52.

Kemény

Koreck

. Ultraviolet light phototherapy for allergic rhinitis. J Photochem Photobiol B. 2007;87:58-65.

53.

Koreck

Csoma

Bodai

, et al. Rhinophototherapy: a new therapeutic tool for the management of allergic rhinitis. J Allergy Clin Immunol. 2005;115:541-547.

54.

Cingi

Cakli

Yaz

Songu

Bal

. Phototherapy for allergic rhinitis: a prospective, randomized, single-blind, placebo-controlled study. Ther Adv Respir Dis. 2010;4:209-213.

55.

Dulguerov

N GN

Courvoisier

Landis

Lacroix

Hauser

. Rhinophototherapy in chronic rhinosinusitis: a double blind randomized placebo-controlled trial. Rhinol J. 2017;55:106.

56.

Koreck

Szechenyi

Morocz

, et al. Effects of intranasal phototherapy on nasal mucosa in patients with allergic rhinitis. J Photochem Photobiol B. 2007;89:163-169.

57.

Mitchell

Paniker

Sanchez

, et al. Molecular response of nasal mucosa to therapeutic exposure to broad-band ultraviolet radiation. J Cell Mol Med. 2010;14:313-322.

58.

Apuhan

Terzi

Kükner

Gök

. Histopathological evaluation of the effect of intranasal phototherapy on nasal mucosa in rabbits. J Photochem Photobiol B. 2011;105:94-97.

59.

Fujii

Kitamura

Mizuguchi

, et al. Effects of irradiation with narrowband-ultraviolet B on up-regulation of histamine H1 receptor mRNA and induction of apoptosis in HeLa cells and nasal mucosa of rats. J Pharmacol Sci. 2018;138:54-62.

60.

Yurttas

Şereflican

Erkoçoğlu

Terzi

Kükner

Oral

. Histopathological effects of intranasal phototherapy and nasal corticosteroids in allergic rhinitis in a rabbit model. J Photochem Photobiol B. 2015;149:289-291.

61.

Husain

Banks

Woodworth

Bleier

. Lightening in a bottle: comparison of ultraviolet light to traditional sterilization in saline irrigations bottles. Int Forum Allergy Rhinol. 2020;10:53-58.

62.

Keil

Ragan

Yonemura

Hartson

Dart

Bowen

. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang. Published online April 20, 2020. doi:10.1111/vox.12937

63.

Kraissl

Cimiotti

Meleney

. Considerations in the use of ultraviolet radiation in operating rooms. Ann Surg. 1940;111:161-185.

64.

Setlow

Grist

Thompson

Woodhead

. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sci U S A. 1993;90:6666-6670.

65.

Balasubramanian

. Ultraviolet radiation and cataract. J Ocul Pharmacol Ther. 2000;16:285-297.

66.

Ponnaiya

Buonanno

Welch

Shuryak

Randers-Pehrson

Brenner

. Far-UVC light prevents MRSA infection of superficial wounds in vivo. PLoS One. 2018;13:e0192053.

67.

Buonanno

Randers-Pehrson

Bigelow

, et al. 207-nm UV light—a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies. PLoS One. 2013;8:e76968.

68.

Winther

Buchert

Turner

Hendley

Tschaikin

. Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am J Rhinol Allergy. 2010;24:374-377.

69.

de Weerd

Samarajiwa

Hertzog

. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007;282:20053-20057.

70.

Ziegler

CGK

Allon

Nyquist

, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. Published online April 27, 2020. doi:10.1016/j.cell.2020.04.035

71.

Cinatl

Morgenstern

Bauer

Chandra

Rabenau

Doerr

. Treatment of SARS with human interferons. Lancet. 2003;362:293-294.

72.

Sun

Jiang

Tien

Liu

. IFN-lambda: a new spotlight in innate immunity against influenza virus infection. Protein Cell. 2018;9:832-837.

73.

Lin

Huang

Zhou

, et al. Efficacy and safety of interferon-alpha2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. Arch Virol. 2016;161:3073-3080.

74.

Djukanovic

Harrison

Johnston

, et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections: a randomized trial. Am J Respir Crit Care Med. 2014;190:145-154.

75.

Meng

Wang

, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. medRxiv. Published online May 7, 2020. doi:10.1101/2020.04.11.20061473

76.

David

Illum

. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet. 2003;42:1107-1128.

77.

Ways

Lau

Khutoryanskiy

. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers. 2018;10:267.

78.

Hong

S-S

Choi

H-G

Lim

S-J

. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11:540.

79.

Bodratti

Alexandridis

. Formulation of poloxamers for drug delivery. J Funct Biomater. 2018;9:11.

80.

Snidvongs

Thanaviratananich

. Update on intranasal medications in rhinosinusitis. Curr Allergy Asthma Rep. 2017;17(7):47.

81.

Djupesland

Skretting

. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012;25:280-289.

82.

Harvey

Debnath

Srubiski

Bleier

Schlosser

. Fluid residuals and drug exposure in nasal irrigation. Otolaryngol Head Neck Surg. 2009;141:757-761.

83.

Aderibigbe

Naki

. Design and efficacy of nanogels formulations for intranasal administration. Molecules. 2018;23.

84.

Dayal

Shaik

Singh

. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci. 2004;93:1725-1742.

85.

Wang

Liu

, et al. In situ gel-forming system: an attractive alternative for nasal drug delivery. Crit Rev Ther Drug Carrier Syst 2013; 30(5): 411-34.

86.

Geisthoff

Blum

Ruppclassen

Plinkert

. Lipid-based nose ointment for allergic rhinitis. Otolaryngol Head Neck Surg. 2005;133:754-761.

87.

Skalny

Rink

Ajsuvakova

, et al. Zinc and respiratory tract infections: perspectives for COVID-19 (Review). Int J Mol Med. 2020;46(1):17-26.

88.

Alexander

Davidson

. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. Laryngoscope. 2006;116(2):217-220.